exRNAdisease

General Information

Database ID:

exR0083398

RNA Name:

TOB2

RNA Type:

mRNA

Chromosome:

chr22

Starnd:

Coordinate:

Start Site(bp):

41433494

End Site(bp):

41446801

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABL1	chr9	130713016	130887675	+
AC004922.1	chr7	99325879	99394653	+
AC008878.3	chr19	7382834	7470241	+
ACBD6	chr1	180269653	180502954	-
ADGRA3	chr4	22345071	22516066	-
AHCY	chr20	34280268	34311802	-
AKAP1	chr17	57085092	57121346	+
AL136295.4	chr14	24180395	24190416	-

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-16-5p	chr3	160404754	160404775	+
hsa-miR-23a-3p	chr19	13836595	13836615	-
hsa-miR-103a-3p	chr5	168560904	168560926	-
hsa-miR-107	chr10	89592756	89592778	-
hsa-miR-34a-5p	chr1	9151735	9151756	-
hsa-miR-23b-3p	chr9	95085265	95085287	+
hsa-miR-135a-5p	chr12	97563834	97563856	+
hsa-miR-195-5p	chr17	7017667	7017687	-
hsa-miR-34c-5p	chr11	111513451	111513473	+
hsa-miR-378a-3p	chr5	149732867	149732888	+
hsa-miR-135b-5p	chr1	205448361	205448383	-
hsa-miR-422a	chr15	63870989	63871010	-
hsa-miR-424-5p	chrX	134546680	134546701	-
hsa-miR-432-5p	chr14	100884496	100884518	+
hsa-miR-512-3p	chr19	53666729	53666750	+
hsa-miR-520a-5p	chr19	53690895	53690915	+
hsa-miR-545-3p	chrX	74287126	74287147	-
hsa-miR-654-5p	chr14	101040234	101040255	+
hsa-miR-708-5p	chr11	79402077	79402099	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC064802.1	chr8	114282067	114295839	+
AD000090.1	chr19	35557956	35581954	+
AL117378.1	chr6	131901963	131920565	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference